Involvement of protein kinase D in Fc gamma-receptor activation of the NADPH oxidase in neutrophils

The Biochemical Journal
Jan K Davidson-MoncadaLodewijk V Dekker

Abstract

Protein kinases involved in the activation of the NADPH oxidase by Fc gamma receptors in neutrophils were studied. Of three different protein kinase C (PKC) inhibitors, Gö 6976 inhibited the NADPH oxidase completely, whereas bisindolylmaleimide I and Ro 31-8220 caused a 70-80% inhibition. Thus a Gö 6976-sensitive, bisindolylmaleimide I/Ro 31-8220-insensitive component contributes to NADPH oxidase activation induced by Fc gamma receptors. Down-regulation of PKC isotypes resulted in inhibition of Fc gamma-receptor-activated NADPH oxidase, but a down-regulation-insensitive component was still present. This component was sensitive to Gö 6976, but insensitive to Ro 31-8220. It has been shown previously that protein kinase D/PKC-mu (PKD) shows this same pharmacology in vitro. We show that PKD is present in neutrophils and that, in contrast with PKC isotypes, PKD is not down-regulated. Therefore PKD may participate in NADPH oxidase activation. To obtain direct evidence for this we adopted an antisense approach. Antisense PKD inhibited NADPH oxidase induced by Fc gamma-receptor stimulation by 50% and the Ro 31-8220-insensitive component in the activation was inhibited by antisense PKD. In vitro kinase assays showed that PKD is activate...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Oct 16, 1978·Biochemical and Biophysical Research Communications·A W Segal, S B Coade
Sep 28, 1990·Biochemical and Biophysical Research Communications·B TwomeyM M Dale
Feb 1, 1990·Trends in Biochemical Sciences·M Baggiolini, M P Wymann
Jan 14, 1986·Biochemical and Biophysical Research Communications·R GennaroD Romeo
Dec 1, 1995·The Journal of Biological Chemistry·A C Newton
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·L C McPhailK A Waite
Jan 20, 1995·The Journal of Biological Chemistry·J V Van LintE Rozengurt
Aug 30, 1994·Proceedings of the National Academy of Sciences of the United States of America·A M ValverdeE Rozengurt
Feb 1, 1994·Trends in Biochemical Sciences·L V Dekker, P J Parker
Dec 1, 1995·Mutation Research·E RozengurtA M Valverde
Dec 1, 1995·Seminars in Cell Biology·F B Wientjes, A W Segal
Aug 8, 1997·The Journal of Biological Chemistry·S A MatthewsE Rozengurt
Feb 7, 1998·The Journal of Biological Chemistry·T Iglesias, E Rozengurt
Oct 9, 1998·The Journal of Biological Chemistry·T IglesiasE Rozengurt
Dec 5, 1998·Biochimica Et Biophysica Acta·M J BottomleyG Panayotou
May 8, 1999·Biochimica Et Biophysica Acta·A HayashiT Saito
Nov 11, 1999·Proceedings of the National Academy of Sciences of the United States of America·B DibbertH U Simon
Nov 24, 1999·FEBS Letters·F J JohannesK Pfizenmaier
Mar 23, 2000·The Biochemical Journal·L V DekkerA W Segal

❮ Previous
Next ❯

Citations

Mar 3, 2011·Journal of Lipid Research·Xue Qiang ZhaoYun Zhang
Aug 26, 2003·FEBS Letters·Dongmin ShaoLodewijk V Dekker
Jul 20, 2010·The International Journal of Biochemistry & Cell Biology·Dongmin ShaoLodewijk V Dekker
Jul 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jeoung-Eun ParkAe-Kyung Yi
Feb 6, 2004·International Journal of Medical Microbiology : IJMM·Kazi Mirajul HoqueManoj K Chakrabarti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.